|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
FibroGen, Inc. Announces Preliminary Clinical Findings on the Positive Effects of FG-4592, Its Investigational HIF-PHI Therapy for Anemia, on Lowering Blood Pressure and Cholesterol in Patients With Chronic Kidney Disease
6/4/2012 10:23:43 AM
SAN FRANCISCO--(BUSINESS WIRE)--FibroGen, Inc., today announced preliminary clinical findings from two ongoing, open-label phase 2 studies demonstrating that FG-4592, its investigational oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor (PHI) therapy for anemia, reduced blood pressure in hypertensive patients, reduced cholesterol levels, and improved the ratio of HDL to LDL in lipid profiles, in patients with chronic kidney disease (CKD). Hypertension and dyslipidemia are two of the major risk factors associated with increasing cardiovascular risk in patients with advanced CKD Stages 3b through 5.
|
|
|
|
|
|
|
|
|
|
|